Reapplix wins 2023 Frost & Sullivan’s Best Practices Technology Innovation Leadership Award
BIRKEROD, Denmark (PRWEB) July 20, 2023 -- Reapplix, a leading company specializing in the biological treatment and management of chronic wounds, today announced it has been awarded a Best Practices Technology Innovation Leadership Award in chronic wound treatment for patients with diabetes by Frost & Sullivan.
Frost & Sullivan’s Technology Innovation Leadership Award recognizes the company that has introduced the best underlying technology for achieving remarkable product and customer success while driving future business value.
“We are so honored to receive this recognition from Frost & Sullivan,” said Kira Rupprecht, Chief Executive Officer at Reapplix. “At Reapplix, our commitment to innovation and customer success comes directly from a passion to draw on the patient’s power to heal to improve patient’s lives. We know that when we partner with clinicians to bring our innovation to patients with diabetes, we are directly impacting the patient’s ability to save their limb and extend their life.”
To address the limitations of wound dressing and centrally processed autologous regenerative therapies for chronic wound management, Reapplix has developed its breakthrough 3C Patch, a U.S. FDA 510(k)-cleared and CE marked autologous platelet-rich plasma gel prepared using the 3C Patch System. Using just 18 milliliters of a patient’s blood collected into the 3C Patch System’s 3C Patch device and then placed into the 3CP Centrifuge, the system can automatically perform proprietary high-speed centrifugation, coagulation, and compaction. All three steps can be performed in 20 minutes through an automated process, allowing healthcare professionals to produce the 3C Patch easily and then directly apply it to the chronic wound, without the need for preservation or additional processing steps.
“Frost & Sullivan commends Reapplix’s innovation with the 3C Patch, which has the potential to improve the standard of care for wound care,” said Neeraj Nitin Jadhav, Industry Analyst at Frost & Sullivan. “We recognize Reapplix’s strong overall performance in chronic wound treatment for those with diabetes and are thrilled to present them with this award.”
Each year, Frost & Sullivan applies a rigorous analytical process to evaluate multiple nominees for each award category before determining the final award recipient. The process involves a detailed evaluation of best practices criteria across two dimensions for each nominated company and the winner is recognized for excelling in many of the criteria in that industry.
For more information, please visit http://www.reapplix.com.
CONTACT
Amanda Critelli
Allison+Partners
ABOUT REAPPLIX
Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. The patented 3CPatch® System is an innovative, evidence-based biological wound therapy made entirely from the patient’s own blood – nothing else. Headquartered in Denmark, with a dedicated sales and distribution team in the US, Reapplix is poised for commercial execution with particular focus on the US market.
ABOUT FROST & SULLIVAN
Frost & Sullivan is the Growth Pipeline Company™. We power our clients to a future shaped by growth. Our Growth Pipeline as a Service™ provides the CEO and the CEO’s growth team with a continuous and rigorous platform of growth opportunities, ensuring long-term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at http://www.frost.com.
Amanda Critelli, Reapplix, https://reapplix.com/, 1 8458676470, [email protected]
Share this article